A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Jun 2015
At a glance
- Drugs Lestaurtinib (Primary)
- Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 18 Jul 2013 Planned end date changed from 1 Dec 2012 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 18 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.